FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283738707> ?p ?o ?g. }

• W4283738707 abstract "Bladder cancer is known to be the most common malignant tumor in the urinary system and has a poor prognosis; thus, new targets for drug treatment are urgently needed. Pyroptosis is defined as programmed cell death in the inflammatory form mediated by the gasdermin protein. It has therapeutic potential due to the synergistic effect of radiotherapy and chemotherapy, can reverse chemotherapy resistance, is able to regulate the body environment to alter tumor metabolism, and may enhance the response rate of the immune checkpoint inhibitor. Accordingly, this study attempted to explore the role of pyroptosis in bladder cancer. A prognostic model based on five pyroptosis-related genes was constructed by conducting univariate Cox survival and LASSO regression analyses using The Cancer Genome Atlas (TCGA) cohort. Patients were divided into high- and low-risk groups according to the median risk score, with all five PRGs having downregulated expression in the high-risk group. The high-risk group was shown to have a worse prognosis than the low-risk group, and survival differences between the two groups were then validated in the Gene Expression Omnibus (GEO) cohort. Moreover, the ROC curves demonstrated the model’s moderate predictive ability. The univariate and multivariate Cox regression analyses indicated that risk scores were found to serve as an independent prognosis factor for OS in bladder cancer patients. In addition, the high-risk group was observed to be associated with advanced N and TNM stages. A nomogram combining risk scores and clinical features was then established, with the ROC curve indicating that the AUC of TCGA training cohort in 3 and 5 years was 0.789 and 0.775, respectively. The calibration curve exhibited a high consistency between the actual survival rate and the predicted rate. Furthermore, the GO and KEGG analyses found that antigen processing and presentation of exogenous antigen, exogenous peptide antigen, and peptide antigen were enriched in the low-risk group. A higher abundance of tumor-infiltrating immune cells and additional active immune pathways were also noted in the low-risk group. In addition, immunotherapy biomarkers, including TMB, PD1, PD-L1, CTLA4, and LAG3, were shown to have higher levels in the low-risk group. Therefore, patients in the low-risk group may be potential responders to immune checkpoint inhibitors." @default.
• W4283738707 created "2022-07-02" @default.
• W4283738707 creator A5027961969 @default.
• W4283738707 creator A5048319214 @default.
• W4283738707 creator A5068313409 @default.
• W4283738707 creator A5083979329 @default.
• W4283738707 creator A5089839498 @default.
• W4283738707 date "2022-07-01" @default.
• W4283738707 modified "2023-10-14" @default.
• W4283738707 title "Pyroptosis-Related Gene to Construct Prognostic Signature and Explore Immune Microenvironment and Immunotherapy Biomarkers in Bladder Cancer" @default.
• W4283738707 cites W1848978402 @default.
• W4283738707 cites W1953948364 @default.
• W4283738707 cites W1985970823 @default.
• W4283738707 cites W2023368253 @default.
• W4283738707 cites W2036710606 @default.
• W4283738707 cites W2092312798 @default.
• W4283738707 cites W2105935489 @default.
• W4283738707 cites W2563094871 @default.
• W4283738707 cites W2583964565 @default.
• W4283738707 cites W2626036386 @default.
• W4283738707 cites W2885385214 @default.
• W4283738707 cites W2886498337 @default.
• W4283738707 cites W2888147674 @default.
• W4283738707 cites W2898289679 @default.
• W4283738707 cites W2898732430 @default.
• W4283738707 cites W2914783575 @default.
• W4283738707 cites W2917837889 @default.
• W4283738707 cites W2947833689 @default.
• W4283738707 cites W2951498948 @default.
• W4283738707 cites W2951509935 @default.
• W4283738707 cites W2983476233 @default.
• W4283738707 cites W2991483425 @default.
• W4283738707 cites W2999534343 @default.
• W4283738707 cites W3011500848 @default.
• W4283738707 cites W3012485477 @default.
• W4283738707 cites W3013422203 @default.
• W4283738707 cites W3029844367 @default.
• W4283738707 cites W3048484045 @default.
• W4283738707 cites W3102493364 @default.
• W4283738707 cites W3104830417 @default.
• W4283738707 cites W3107880858 @default.
• W4283738707 cites W3110194301 @default.
• W4283738707 cites W3126318561 @default.
• W4283738707 cites W3142080073 @default.
• W4283738707 cites W3144571741 @default.
• W4283738707 cites W3157311882 @default.
• W4283738707 cites W3171550932 @default.
• W4283738707 cites W3180091720 @default.
• W4283738707 cites W3195292091 @default.
• W4283738707 cites W3197288945 @default.
• W4283738707 doi "https://doi.org/10.3389/fgene.2022.801665" @default.
• W4283738707 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35846123" @default.
• W4283738707 hasPublicationYear "2022" @default.
• W4283738707 type Work @default.
• W4283738707 citedByCount "3" @default.
• W4283738707 countsByYear W42837387072023 @default.
• W4283738707 crossrefType "journal-article" @default.
• W4283738707 hasAuthorship W4283738707A5027961969 @default.
• W4283738707 hasAuthorship W4283738707A5048319214 @default.
• W4283738707 hasAuthorship W4283738707A5068313409 @default.
• W4283738707 hasAuthorship W4283738707A5083979329 @default.
• W4283738707 hasAuthorship W4283738707A5089839498 @default.
• W4283738707 hasBestOaLocation W42837387071 @default.
• W4283738707 hasConcept C121608353 @default.
• W4283738707 hasConcept C126322002 @default.
• W4283738707 hasConcept C143998085 @default.
• W4283738707 hasConcept C17172800 @default.
• W4283738707 hasConcept C2776914184 @default.
• W4283738707 hasConcept C2777209026 @default.
• W4283738707 hasConcept C2777701055 @default.
• W4283738707 hasConcept C2780352672 @default.
• W4283738707 hasConcept C34626388 @default.
• W4283738707 hasConcept C50382708 @default.
• W4283738707 hasConcept C71924100 @default.
• W4283738707 hasConcept C72563966 @default.
• W4283738707 hasConceptScore W4283738707C121608353 @default.
• W4283738707 hasConceptScore W4283738707C126322002 @default.
• W4283738707 hasConceptScore W4283738707C143998085 @default.
• W4283738707 hasConceptScore W4283738707C17172800 @default.
• W4283738707 hasConceptScore W4283738707C2776914184 @default.
• W4283738707 hasConceptScore W4283738707C2777209026 @default.
• W4283738707 hasConceptScore W4283738707C2777701055 @default.
• W4283738707 hasConceptScore W4283738707C2780352672 @default.
• W4283738707 hasConceptScore W4283738707C34626388 @default.
• W4283738707 hasConceptScore W4283738707C50382708 @default.
• W4283738707 hasConceptScore W4283738707C71924100 @default.
• W4283738707 hasConceptScore W4283738707C72563966 @default.
• W4283738707 hasLocation W42837387071 @default.
• W4283738707 hasLocation W42837387072 @default.
• W4283738707 hasLocation W42837387073 @default.
• W4283738707 hasOpenAccess W4283738707 @default.
• W4283738707 hasPrimaryLocation W42837387071 @default.
• W4283738707 hasRelatedWork W2920996053 @default.
• W4283738707 hasRelatedWork W3048904743 @default.
• W4283738707 hasRelatedWork W3080602383 @default.
• W4283738707 hasRelatedWork W3095136102 @default.
• W4283738707 hasRelatedWork W3112402561 @default.
• W4283738707 hasRelatedWork W3131814850 @default.
• W4283738707 hasRelatedWork W3211307483 @default.
• W4283738707 hasRelatedWork W4206088420 @default.

• next